Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study seeks to spot hidden muscle loss in heart failure patients

NCT ID NCT06217640

Diagnosis Sponsor: University of Liverpool Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at 80 people with heart failure to find better ways to diagnose sarcopenia, a condition where muscles weaken and shrink. Researchers will use body scans, blood tests, and simple physical tests like walking speed and grip strength. The goal is to catch muscle loss early, which could help improve quality of life and reduce hospital visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better and earlier diagnosis of muscle weakness in heart failure patients, helping doctors tailor treatments and improve outcomes.
What could go wrong
This is an observational study with only 80 participants, so results may not apply to all heart failure patients. The tests are exploratory and not yet proven to improve diagnosis in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Older men and women with and without HF are targeted following a screening of medical records from the Liverpool Hospital Foundation NHS Trust HF clinic. Our usual practice is to recruit the non-HF controls by community approach.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for HF: 1. Clinically diagnosed HF regardless of ejection fraction rate (both HFrEF and HFpEF). 2. Age 50 years and older. 3. BMI more than 18 and less than 30 kg/m\^2. 4. Must be on optimal medical treatment for three months prior to inclusion. 5. Do not have contraindications to providing a blood sample. 6. Sufficient mental capacity to consent as determined by the researchers. 7. Able to walk with or without a walker for at least 16 m. 8. No objection to the researchers contacting their general practitioner and neurologist. Exclusion criteria for HF: 1. Receiving treatment with antibiotics, probiotics, or fish oil during the last 3 months prior to inclusion. 2. Major comorbidities (i.e., cancer, Alzheimer's, type 2 diabetes, chronic kidney disease). 3. Treatment with immunosuppressive drugs. 4. Concurrent infections, or bowel disease. 5. Patients who had received cardiac resynchronization therapy during the past 6 months will not be included. 6. Participants must also not be on any other clinical trial during the study. Inclusion criteria for Healthy controls: 1. No history of chronic disease and will be screened for hypertension. 2. BMI more than 18 and less than 30 kg/m\^2. 3. Although other cardiovascular conditions will be exclusionary, treated hypercholesterolemia and controlled hypertension will be allowed in the healthy group to allow the representation of elderly subjects within this cohort.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Body weight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Body Weight Frailty heart failure Muscle Weakness Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Body weight Frailty Heart failure Muscle weakness Sarcopenia

Contacts and locations

Locations

  • Liverpool University Hospitals NHS Foundation Trust

    Liverpool, Merseyside, L97AL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.